S&P 500   3,002.52 (+0.43%)
DOW   27,048.38 (+0.17%)
QQQ   194.10 (+0.55%)
AAPL   235.08 (+0.30%)
FB   189.73 (+0.09%)
MSFT   140.62 (+0.15%)
GOOGL   1,251.74 (+0.70%)
AMZN   1,793.13 (+0.88%)
NVDA   196.23 (+1.04%)
MU   45.91 (+1.66%)
BABA   176.75 (-0.21%)
GE   8.97 (+0.67%)
TSLA   262.31 (+0.99%)
AMD   31.15 (+1.10%)
T   37.78 (-0.03%)
F   9.08 (+0.11%)
ACB   3.77 (+4.43%)
PRI   124.44 (+0.46%)
NFLX   303.93 (+6.17%)
BAC   30.36 (+0.63%)
GILD   65.66 (+0.47%)
DIS   130.60 (-0.21%)
S&P 500   3,002.52 (+0.43%)
DOW   27,048.38 (+0.17%)
QQQ   194.10 (+0.55%)
AAPL   235.08 (+0.30%)
FB   189.73 (+0.09%)
MSFT   140.62 (+0.15%)
GOOGL   1,251.74 (+0.70%)
AMZN   1,793.13 (+0.88%)
NVDA   196.23 (+1.04%)
MU   45.91 (+1.66%)
BABA   176.75 (-0.21%)
GE   8.97 (+0.67%)
TSLA   262.31 (+0.99%)
AMD   31.15 (+1.10%)
T   37.78 (-0.03%)
F   9.08 (+0.11%)
ACB   3.77 (+4.43%)
PRI   124.44 (+0.46%)
NFLX   303.93 (+6.17%)
BAC   30.36 (+0.63%)
GILD   65.66 (+0.47%)
DIS   130.60 (-0.21%)
Log in

DiaMedica Therapeutics Stock Price, News & Analysis (NASDAQ:DMAC)

$2.41
-0.02 (-0.82 %)
(As of 10/17/2019 09:48 AM ET)
Today's Range
$2.41
Now: $2.41
$2.41
50-Day Range
$1.78
MA: $2.50
$3.00
52-Week Range
$1.70
Now: $2.41
$5.93
Volume201 shs
Average Volume47,783 shs
Market Capitalization$28.94 million
P/E RatioN/A
Dividend YieldN/A
Beta2.77
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DMAC
CUSIPN/A
CIKN/A
Phone763-312-6755

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$500,000.00
Book Value$1.43 per share

Profitability

Net Income$-5,730,000.00

Miscellaneous

Employees9
Market Cap$28.94 million
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive DMAC News and Ratings via Email

Sign-up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter.


DiaMedica Therapeutics (NASDAQ:DMAC) Frequently Asked Questions

What is DiaMedica Therapeutics' stock symbol?

DiaMedica Therapeutics trades on the NASDAQ under the ticker symbol "DMAC."

How were DiaMedica Therapeutics' earnings last quarter?

DiaMedica Therapeutics Inc (NASDAQ:DMAC) announced its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.07. View DiaMedica Therapeutics' Earnings History.

When is DiaMedica Therapeutics' next earnings date?

DiaMedica Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for DiaMedica Therapeutics.

What price target have analysts set for DMAC?

3 analysts have issued 1 year target prices for DiaMedica Therapeutics' stock. Their predictions range from $8.00 to $11.00. On average, they anticipate DiaMedica Therapeutics' stock price to reach $9.33 in the next twelve months. This suggests a possible upside of 287.3% from the stock's current price. View Analyst Price Targets for DiaMedica Therapeutics.

What is the consensus analysts' recommendation for DiaMedica Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DiaMedica Therapeutics.

Has DiaMedica Therapeutics been receiving favorable news coverage?

News stories about DMAC stock have been trending very negative recently, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. DiaMedica Therapeutics earned a coverage optimism score of -3.2 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for DiaMedica Therapeutics.

Are investors shorting DiaMedica Therapeutics?

DiaMedica Therapeutics saw a decrease in short interest during the month of September. As of September 30th, there was short interest totalling 4,300 shares, a decrease of 61.6% from the August 30th total of 11,200 shares. Based on an average trading volume of 50,400 shares, the short-interest ratio is currently 0.1 days. Approximately 0.1% of the shares of the company are sold short. View DiaMedica Therapeutics' Current Options Chain.

Who are some of DiaMedica Therapeutics' key competitors?

What other stocks do shareholders of DiaMedica Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include Datasea (DTSS), Adamis Pharmaceuticals (ADMP), Alector (ALEC), Aptose Biosciences (APTO), Arcturus Therapeutics (ARCT), Aurinia Pharmaceuticals (AUPH), Baidu (BIDU), Capricor Therapeutics (CAPR), Costco Wholesale (COST) and Cray (CRAY).

Who are DiaMedica Therapeutics' key executives?

DiaMedica Therapeutics' management team includes the folowing people:
  • Mr. Rick Pauls M.B.A., MBA, Pres, CEO & Director (Age 48)
  • Mr. Scott B. Kellen C.A., CFO & Company Sec. (Age 54)
  • Dr. Todd A. Verdoorn, Chief Scientific Officer (Age 57)
  • Mr. Edward B. Rady, Chief Commercial Advisor (Age 70)
  • Dr. Dennis D. Kim M.D., MBA, Consulting Chief Medical Officer (Age 49)

When did DiaMedica Therapeutics IPO?

(DMAC) raised $18 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 4,000,000 shares at $4.00-$5.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO.

How do I buy shares of DiaMedica Therapeutics?

Shares of DMAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is DiaMedica Therapeutics' stock price today?

One share of DMAC stock can currently be purchased for approximately $2.41.

How big of a company is DiaMedica Therapeutics?

DiaMedica Therapeutics has a market capitalization of $28.94 million and generates $500,000.00 in revenue each year. DiaMedica Therapeutics employs 9 workers across the globe.View Additional Information About DiaMedica Therapeutics.

What is DiaMedica Therapeutics' official website?

The official website for DiaMedica Therapeutics is http://www.diamedica.com/.

How can I contact DiaMedica Therapeutics?

DiaMedica Therapeutics' mailing address is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. The company can be reached via phone at 763-312-6755 or via email at [email protected]


MarketBeat Community Rating for DiaMedica Therapeutics (NASDAQ DMAC)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  47 (Vote Outperform)
Underperform Votes:  61 (Vote Underperform)
Total Votes:  108
MarketBeat's community ratings are surveys of what our community members think about DiaMedica Therapeutics and other stocks. Vote "Outperform" if you believe DMAC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DMAC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Featured Article: What is the Current Ratio?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel